{{Rsnum
|rsid=1130609
|Gene=RRM2
|Chromosome=2
|position=10122793
|Orientation=plus
|GMAF=0.3462
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(G;G)
|geno2=(G;T)
|geno3=(T;T)
|Gene_s=RRM2
}}{{ population diversity
| geno1=(G;G)
| geno2=(G;T)
| geno3=(T;T)
| CEU | 52.3 | 43.1 | 4.6
| HCB | 15.6 | 42.2 | 42.2
| JPT | 11.4 | 47.7 | 40.9
| YRI | 96.8 | 3.2 | 0.0
| ASW | 0.0 | 0.0 | 0.0
| CHB | 15.6 | 42.2 | 42.2
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}

{{Venter SNP
|rsid=1130609
|allele=G
|frequency=0.258
|uid=1103658020441
|type=heterozygous_SNP
|hugo=RRM2
|ensembl gene=ENSG00000171848
|ensembl transcript=ENST00000360566
|sift=
|disease=Ribonucleotide reductase is thought to mediate the pathogenesis of the immunodeficiency of adenosine deaminase or purine nucleoside phosphorylase. The deoxynucleotides that accumulate in the lymphoid cells of these patients are thought to feed-back inhibit ribonucleotide reductase, preventing DNA replication and cell proliferation.
}}

{{GET Evidence
|gene=RRM2
|aa_change=Ser59Ala
|aa_change_short=S59A
|impact=not reviewed
|qualified_impact=Insufficiently evaluated not reviewed
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs1130609
|n_genomes=1
|n_genomes_annotated=0
|n_haplomes=2
|n_articles=0
|n_articles_annotated=0
|nblosum100=-1
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}